1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,160 | 4,280 | 05.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.11. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | 217 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
19.11.2025 / 11:11 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 17.11. | XFRA 4RD: WIEDERAUFNAHME/RESUMPTION | 97 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 14.11. | MaaT Pharma Announces the Successful Completion of Its Global Offering of €9.1 Million | 345 | Business Wire | Regulatory News:
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO... ► Artikel lesen | |
| 14.11. | XFRA 4RD: AUSSETZUNG/SUSPENSION | 208 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMAAT PHARMA S.A.... ► Artikel lesen | |
| 13.11. | MaaT Pharma Launches a Capital Increase of Approximately €9 Million | 430 | Business Wire | Launch of a Global Offering of new ordinary shares for approximately €9 million through a Private Placement aimed at qualified investors, and a PrimaryBid Offering aimed at retail investors via... ► Artikel lesen | |
| 05.11. | MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 | 322 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 04.11. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | 231 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
04.11.2025 / 11:37 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 04.11. | MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update | 280 | Business Wire | The Company received an upfront payment of €10.5 million in July 2025 after the signature of an exclusive license and distribution agreement with Clinigen. Subject to approval and grant of a Marketing... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 03.11. | MaaT Pharma's Xervyteg shows 62% response rate in GI-aGvHD trial | 5 | Investing.com | ||
| 03.11. | MaaT Pharma: Xervyteg erzielt 62 % Ansprechrate in entscheidender Studie zu GI-aGvHD | 4 | Investing.com Deutsch | ||
| 03.11. | MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025 | 277 | Business Wire | Oral presentation at ASH 2025 to feature pivotal Phase 3 results of Xervyteg (MaaT013), including previously disclosed primary endpoint data (62% GI-ORR at Day 28) and new findings on secondary... ► Artikel lesen | |
| 07.10. | MaaT Pharma stock jumps 11% after DSMB clears Phase 2b trial to continue | 6 | Investing.com | ||
| 07.10. | MaaT Pharma's MaaT033 For Allo-HSCT Patients Clears Second DSMB Safety Review In Phase 2b Trial | 2 | RTTNews | ||
| 07.10. | MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 292 | Business Wire | The DSMB conducted an unblinded safety review of data from the first 120 enrolled patients and identified no safety concerns and no excessive mortality related to MaaT033 as of today. The... ► Artikel lesen | |
| 17.09. | MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update | 481 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
| 30.07. | MaaT Pharma: €37.5 Million EIB Loan Secured To Advance Cancer Therapies | 3 | pulse2.com | ||
| 28.07. | MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology | 571 | Business Wire | Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg currently under review for potential approval by the EMA and MaaT033... ► Artikel lesen | |
| 24.07. | MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux | 305 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 07.07. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 321 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 02.07. | MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg in acute Graft-versus Host Disease in Europe | 554 | Business Wire | MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg(MaaT013), its first in class treatment proposed for patients... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 49,250 | +0,82 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,110 | -1,58 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,021 | -1,77 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| MICROBOT MEDICAL | 2,040 | +0,39 % | Microbot Medical is a buy, Roth says | ||
| ATAI BECKLEY | 3,687 | -0,75 % | Atai Beckley reicht nach Beckley-Psytech-Übernahme Prospektnachtrag ein | ||
| BIOMERIEUX | 104,80 | 0,00 % | BIOMERIEUX: bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health | ||
| BIOXCEL THERAPEUTICS | 1,762 | -1,89 % | BioXcel Therapeutics: Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions | ||
| CYBIN | 5,250 | +1,94 % | Cybin Inc.: Cybin to Participate in the Jefferies Global Healthcare Conference in London | Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 1,475 | +10,60 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| PDS BIOTECHNOLOGY | 0,760 | +2,15 % | PDS Biotech secures FDA meeting to discuss accelerated approval pathway | ||
| GENUS | 30,200 | +3,42 % | Dividendenbekanntmachungen (06.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AIRTEL AFRICA PLC GB00BKDRYJ47 0,0216 GBP 0,0245 EUR ARMSTRONG WORLD INDUSTRIES INC US04247X1028 0,339 USD 0,2949 EUR ASHMORE GROUP... ► Artikel lesen | |
| ANAPTYSBIO | 37,800 | -1,05 % | GSK und AnaptysBio verklagen einander wegen angeblicher Lizenzverstöße | DJ GSK und AnaptysBio verklagen einander wegen angeblicher Lizenzverstöße
Von Elena Vardon
DOW JONES--Der Arzneimittelhersteller GSK und das US-Biotechunternehmen AnaptysBio haben einen Rechtsstreit... ► Artikel lesen | |
| ABIONYX PHARMA | 3,770 | -3,08 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,660 | -2,22 % | XTL Biopharmaceuticals ernennt Niv Segal zum neuen Finanzvorstand | ||
| AKESO | 13,300 | -1,48 % | Akeso, Inc.: Akeso's Bispecific Antibody Targeting Aß and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China | HONG KONG, Nov. 16, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aß) and... ► Artikel lesen |
MAAT PHARMA SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,230 Euro und damit +1,20 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.